目的 系統(tǒng)評(píng)價(jià)異甘草酸鎂靜輔助治療重癥急性胰腺炎（SAP）的有效性和安全性。方法 計(jì)算機(jī)檢索中國(guó)學(xué)術(shù)期刊全文數(shù)據(jù)庫(kù)（CNKI）、維普中文期刊全文數(shù)據(jù)庫(kù)（VIP）、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)（CBM）、萬方數(shù)據(jù)庫(kù)、PubMed、EmBase和The Cochrane Library數(shù)據(jù)庫(kù)有關(guān)常規(guī)治療聯(lián)合異甘草酸鎂（試驗(yàn)組）對(duì)比常規(guī)治療（對(duì)照組）治療SAP的隨機(jī)對(duì)照試驗(yàn)（RCTs），檢索時(shí)間為從建庫(kù)到2020年10月。提取數(shù)據(jù)、評(píng)價(jià)文獻(xiàn)質(zhì)量后，采用RevMan 5.3軟件進(jìn)行Meta分析。結(jié)果 最終納入12篇RCTs和1 161例受試者。Meta分析結(jié)果顯示：試驗(yàn)組臨床有效率[RR=1.23，95% CI=（1.17，1.30），P<0.01]顯著大于對(duì)照組；試驗(yàn)組CRP水平下降值[SMD=-1.67，95% CI=（-2.41，-0.93），P<0.01]、TNF-α水平下降值[SMD=-1.17，95% CI=（-1.55，-0.78），P<0.01]和IL-6水平下降值[SMD=-1.40，95% CI=（-1.86，-0.94），P<0.01]均顯著大于對(duì)照組；試驗(yàn)組治療后ALT水平[SMD=-2.35，95% CI=（-2.90，-1.79），P<0.01]和AST水平[SMD=-1.77，95% CI=（-2.46，-1.08），P<0.01]均顯著小于對(duì)照組。ADR發(fā)生率組間比較無顯著性差異[RR=1.49，95% CI=（0.88，2.54），P=0.14]。結(jié)論 異甘草酸鎂能顯著降低SAP患者炎性因子，改善肝腎功能，減少臨床體征改善時(shí)間，改善早期預(yù)后，且安全性好。

Objective To evaluate the efficacy and safety of magnesium isoglycyrrhizinate in the adjuvant treatment of the patients with severe acute pancreatitis (SAP). Methods Randomized controlled trials (RCTs) about the routine treatment combined with magnesium isoglycyrrhizinate (test group) compared with the routine treatment (control group) in the treatment of SAP was searched in CNKI, Wanfang, VIP, CBM, PubMed EmBase and the Cochrane Library databases from inception to October 2020 by computer. Meta-analysis was performed on the homogeneous study using RevMan 5.3 software after screened the literature, evaluated the quality of included studies. Results A total of 12 RCTs and 1 161 patients were included. The Metaanalysis showed that the test group of the clinical effective rate[RR=1.23, 95%CI=(1.17, 1.30), P < 0.01] was significantly higher than that in the control group; the test group of the decrease values of CRP levels[SMD=1.67, 95%CI=(2.41, 0.93), P < 0.01], TNFα levels[SMD=-1.17, 95%CI=(-1.55, -0.78), P < 0.01] and IL-6 levels[SMD=-1.40, 95%CI=(-1.86, -0.94), P < 0.01] were all significantly higher than those in the control group; after the treatment, the test group of ALT levels[SMD=-2.35, 95%CI=(-2.90, -1.79), P < 0.01] and AST levels[SMD=-1.77, 95%CI=(-2.46, -1.08), P < 0.01] were all significantly lower than those in the control group. There was no significant difference in rate of ADR[RR=1.49, 95%CI=(0.88, 2.54), P =0.14]. Conclusion Magnesium isoglycyrrhizinate can significantly reduce inflammatory factors, improve liver and kidney function, reduce clinical signs to improve the time, improve early prognosis, meanwhile with good safety.

R286.5

衡水市科技計(jì)劃項(xiàng)目（2019014059Z）